GSK Terminates $1.36B STING-ADC Collaboration with Mersana, Exits XMT-2056 Development

On April 29, 2026, local time, GSK disclosed in its Q1 financial report that XMT-2056 has been officially removed from the Phase I clinical pipeline. This announcement also marks the end of a partnership between the pharmaceutical giant and Mersana Therapeutics ("Mersana"), which began in 2022 and was once valued at up to $1.36 billion (approximately 9.3 billion RMB).

 

Despite GSK having paid $100 million upfront for this deal and an additional $15 million milestone payment in 2025, the accumulation of clinical safety data and evolving internal strategy led to the ultimate decision to cut losses in a timely manner.

XMT-2056, From a High-Profile Collaboration to a Quiet Exit

Let's go back to 2022.

 

At that time, the ADC track was on the verge of an explosion. GSK paid Mersana $100 million in cash for the exclusive co-development and commercialization option of XMT-2056. If GSK ultimately exercises this option, Mersana could receive up to $1.36 billion. This amount would rank among the top-tier deals for preclinical ADC assets at that time.

 

XMT-2056, born from Mersana's immunosynthetic platform, is a STING agonist ADC targeting HER2-positive tumors. Unlike ADCs that rely on traditional cytotoxic payloads, its mechanism of action involves activating the STING signaling pathway to mobilize the body’s innate immune system to attack cancer cells. Theoretically, this could be considered a "smarter" way of inducing cell death.

 

Preclinical studies show that in co-culture experiments, even when the number of HER2-negative cells is four times that of positive cells, XMT-2056 can still induce immune-mediated killing of negative cells in the presence of HER2-positive cells. This effect may stem from ADC-induced antigen-dependent STING activation in monocytes, leading to the release of soluble factors. This represents a mechanism of action entirely different from the classic ADC "bystander effect."

 

The traditional bystander effect relies on the diffusion of cytotoxic payloads from the microenvironment to neighboring cells, with the killing range limited by the quantity and diffusion capacity of the payload. In contrast, immune-mediated killing has a conceptual advantage—it is not restricted by the number of payloads but instead mobilizes the immune system for a broader attack.

 

These data suggest that XMT-2056 may still produce clinically meaningful anti-tumor activity, even in tumors with highly heterogeneous antigen expression.

 

According to Mersana's original plan, XMT-2056 was scheduled to initiate Phase I clinical trials in multiple tumor types, including breast cancer, gastric cancer, and non-small cell lung cancer. In May 2022, the drug also received orphan drug designation for gastric cancer from the FDA, and its prospects were once highly regarded.

 

It is clear that the activation of the STING pathway is highly potent in inducing a Type I interferon response, but its narrow safety window remains a significant challenge for CMC and linker stability. Soon after entering clinical trials, XMT-2056 quickly revealed issues.

 

In March 2023, a treatment-related death occurred in a Phase I trial, prompting Mersana to voluntarily halt the trial. The FDA subsequently issued a clinical hold. In October of the same year, the FDA lifted the hold, and Mersana reduced the starting dose for dose escalation, but the safety concerns have not been fully resolved.

 

During the same period, Mersana's another core ADC product, UpRi, fell into a deeper crisis. The FDA partially suspended its clinical trials due to five severe bleeding-related deaths during the trials. Subsequent expansion studies failed to deliver convincing efficacy data, leading Mersana to lay off 50% of its staff and ultimately abandon UpRi entirely. The company as a whole became unsustainable and was eventually acquired by Day One.

 

It is worth mentioning that, amid this series of upheavals, GSK has consistently maintained a wait-and-see attitude. Although it paid a $15 million milestone payment last year to demonstrate continued interest in the project, it has never formally exercised the option to include XMT-2056 in its own pipeline.

 

Now, the termination decision has officially taken effect. According to Fierce Biotech, the decision was made after GSK reviewed the existing clinical data.

Safety Issues Become the Hidden Killer in ADC Development

The failure of XMT-2056 is not an isolated case but further highlights a repeatedly validated pain point in the ADC field: safety issues are becoming the biggest hidden killer in ADC research and development.。

 

The mechanism of action of STING agonists involves attacking tumors by activating the innate immune system. However, the challenge with this mechanism is that overactivation of the STING pathway may trigger systemic inflammatory responses, leading to severe immune-related toxicity. In the case of XMT-2056, serious bleeding events occurred during clinical trials, including five patient deaths. These incidents represent extreme manifestations of such systemic toxicity.

 

But this is not a problem unique to Mersana.

 

First of all, it should be pointed out that,Safety events have become one of the core reasons for ADC clinical failures.From the premature release of payload due to linker instability to on-target/off-tumor toxicity related to the target, the complex structure of ADC makes its safety issues more unpredictable and harder to control than traditional chemotherapy.

 

Further toSTING-ADC Technology Route Faces More Severe Challenges.Strategies to activate the immune system, while theoretically more promising, have a more pronounced double-edged sword effect. After all, while this design can kill tumors, it may also cause irreversible damage to normal tissues. The termination of XMT-2056 has put the entire STING-ADC track on high alert.

 

At the same time,Regulatory agencies are becoming less tolerant of ADC safety incidents.The FDA's consecutive clinical holds on UpRi and XMT-2056 indicate that regulatory agencies undoubtedly have a zero-tolerance policy towards fatalities, pushing pharmaceutical companies to establish stricter safety evaluation standards during the early stages of development.

 

In other words, the failure of XMT-2056 further highlights an important warning: the competition in ADCs has long shifted from efficacy comparison to ensuring efficacy while also improving safety.

Betting on China-produced ADC, further focusing on the layout

As for GSK, the abandonment of XMT-2056 does not signify a complete retreat from the ADC field; rather, it reflects a more focused strategy and rational allocation of resources.

 

GSK currently has an approved ADC drug for multiple myeloma, Blenrep (targeting BCMA), which is the world's first approved BCMA-targeted ADC. Although Blenrep was previously withdrawn due to a failed confirmatory trial, GSK has not given up and is advancing again with a new clinical design.

 

In early April 2026, GSK announced plans to advance five Phase III clinical trials in the coming months, testing the B7-H4-targeted ADC (mocertatug rezetecan, hereinafter referred to as Mo-Rez) licensed from Hansoh Pharma. This move indicates that GSK's investment in the ADC field is not shrinking but rather intensifying.

 

On April 12, GSK also announced positive results from the global Phase I clinical trial BEHOLD-1 of Mo-Rez. At the highest dose evaluated, Mo-Rez monotherapy achieved a confirmed PROC ORR of 62% and EC ORR of 67% in recurrent or advanced endometrial cancer (EC), with persistence still observed at a median follow-up of 4 to 6 months.

 

Under this logic, continuing to invest resources in an early-stage project with unclear clinical prospects and originating from an already acquired company neither aligns with GSK's current strategic priorities nor conforms to the mainstream deployment model of MNCs.

 

Not only that, but GSK also announced the suspension of the development of the mRNA avian influenza vaccine GSK5536522, as well as the termination of the TLR8 agonist GSK5251738 for chronic hepatitis B. Global pharmaceutical giants are scrutinizing their pipeline assets with unprecedented stringent standards; projects with subpar safety, no matter how novel the concept, will be decisively abandoned.

 

For the ADC track, this incident provides at least some insights. First, safety verification should be moved forward. In traditional ADC development, safety evaluations often begin only during the toxicology phase. However, the lessons from XMT-2056 and UpRi indicate that systematic assessments of linker stability, payload release kinetics, and bystander effects should logically be completed during the molecular design stage.

 

At the same time, the technical route of STING-ADC needs to be re-examined and evaluated. The "double-edged sword" effect of immune agonist ADCs may require a completely new molecular design logic to achieve more precise tumor-specific release, more controllable immune activation intensity, and a more comprehensive toxicity management strategy.

 

As for BD transactions, the logic of pricing is also changing. In 2022, GSK made a $100 million upfront payment bet on a preclinical STING-ADC, which was considered a bold gamble at the time. In hindsight, this deal might indeed have had an element of "gambling" from the start. In future ADC-related BD transactions, the weight of safety data in pricing may significantly increase.